Nasdaq moved to delist TNL Mediagene in June. After an appeals hearing in August, the company has won more time — but must clear two compliance tests before the end of October or face removal from the exchange.
The sequence that brought things to this point began on June 22, when Nasdaq's listing qualifications staff determined to delist TNL Mediagene, citing failure to regain compliance with the minimum bid price rule and existing non-compliance with the stockholders' equity rule. The company requested a hearing a week later. That hearing took place on August 4, and the Nasdaq Hearings Panel issued its ruling on August 23.
The panel set two conditions. By September 21, TNL Mediagene must demonstrate compliance with the minimum bid price requirement — the rule that sets a floor on how low a listed stock can trade. By October 30, it must show its stockholders' equity is sufficient for continued listing. The filing does not say what the company has proposed to do to satisfy either condition.
Shares closed 43.29% higher at $0.5700 after the panel's ruling became public, on dollar volume of about $129 million.
The panel has kept the power to withdraw the exception at any point. If any development during the grace period makes continued listing inadvisable — in the panel's judgment — it can act. TNL Mediagene's own filing says there is no assurance the company will meet the conditions, and a failure on either would result in delisting.
TNL Mediagene had already failed the bid price rule once before June 22 — that failure was what triggered the determination to delist. It now has until September 21 to fix that, and has not said how.